Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $90.49M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.25M
Average 0.19M
Dividends
Genelux Corporation dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Genelux Corporation compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Alpha Tau Medical Ltd NASDAQ:DRTS | $1.24B | 0.00% | $0.00 | 0.00% | 0.00% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | 0.00% | $0.00 | 0.00% | 0.00% |
Candel Therapeutics, Inc. NASDAQ:CADL | $474.42M | 0.00% | $0.00 | 0.00% | 0.00% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | 0.00% | $0.00 | 0.00% | 0.00% |
Contineum Therapeutics, Inc. NASDAQ:CTNM | $348.58M | 0.00% | $0.00 | 0.00% | 0.00% |
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | $235.59M | 0.00% | $0.00 | 0.00% | 0.00% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | 0.00% | $0.00 | 0.00% | 0.00% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | 0.00% | $0.00 | 0.00% | 0.00% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | 0.00% | $0.00 | 0.00% | 0.00% |
Aldeyra The NASDAQ:ALDX | $38.86M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about GNLX's dividend, answered from reported figures.
Does GNLX stock pay dividends?
Genelux Corporation (GNLX) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is GNLX's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.